Tirzepatide — ≥99% Research Peptide

Dual-Action GIP/GLP-1 — Next-Gen Metabolic Peptide

Tirzepatide is the first dual GLP-1/GIP receptor agonist. It simultaneously activates two incretin receptors, producing synergistic effects that exceed either pathway alone.

Research Applications & Benefits

Doses Used in Published Studies

Literature values for laboratory reference only — not dosing guidance.

ModelDoseRouteDurationRef
Human, adults with obesity (SURMOUNT-1)5 mg, 10 mg or 15 mgSubcutaneous, once weekly72 weeks[1]

Laboratory Handling

References

  1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. PMID 35658024

Product Specifications

Compound
Tirzepatide
CAS Number
2023788-19-2
Molecular Weight
4813.45 g/mol
HPLC Purity Specification
≥99%
Category
GLP-1 & Metabolic
Starting Price
$89.00 USD
Country of Origin
United States
Shipping
Cold-chain insulated packaging, fast domestic delivery
Payment
Card, ACH, and cryptocurrency (10% discount)

Quality & Verification

Tirzepatide carries the purity specification shown above. Where a lot-specific CertikLabs Certificate of Analysis is available, the product page links its HPLC purity, LC-MS identity, and concentration results.

Frequently Asked Questions

Is Tirzepatide suitable for human consumption?

No. Tirzepatide is sold strictly for in-vitro laboratory research. It is not a drug, supplement, cosmetic, or food product and must not be administered to humans or animals.

What purity is Tirzepatide?

Tirzepatide carries a ≥99% HPLC purity specification. Check the product page for an available lot report.

How is Tirzepatide shipped and stored?

Vials are shipped lyophilized in temperature-controlled packaging. Store unopened lyophilized peptide at −20°C; once reconstituted with bacteriostatic water, store at 2–8°C and use within 28 days.

Research Use Only. This product is intended for licensed laboratory research and is not for human or veterinary use.